Ultragenyx Pharmaceutical Inc expected to post a loss of $1.45 a share - Earnings Preview

Reuters

2024-11-02

* Ultragenyx Pharmaceutical Inc is expected to show a rise in quarterly revenue when it reports results on November 5 for the period ending September 30 2024

* The Novato California-based company is expected to report a 38.5% increase in revenue to $135.794 million from $98.05 million a year ago, according to the mean estimate from 16 analysts, based on LSEG data.

* LSEG's mean analyst estimate for Ultragenyx Pharmaceutical Inc is for a loss of $1.45 per share.

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 20 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."

* The mean earnings estimate of analysts was unchanged in the last three months.

* Wall Street's median 12-month price target for Ultragenyx Pharmaceutical Inc is $82.00, above its last closing price of $50.99.

Previous quarterly performance (using preferred earnings measure in US dollars).

QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI

ENDING ARTESTIMAT ESTIMATE MET, SE %

E® MISSED

Jun. 30 2024 -1.66 -1.69 -1.52 Beat 10.3

Mar. 31 2024 -1.76 -1.73 -2.03 Missed -17.2

Dec. 31 2023 -1.66 -1.62 -1.52 Beat 6.1

Sep. 30 2023 -2.28 -2.08 -2.23 Missed -7.3

Jun. -2.08 -2.07 -2.25 Missed -8.5

30 2023

Mar. 31 2023 -2.04 -1.98 -2.33 Missed -17.9

Dec. 31 2022 -2.19 -2.14 -2.16 Missed -0.8

Sep. 30 2022 -2.35 -1.81 -3.50 Missed -93

This summary was machine generated November 2 at 03:56 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2480818336"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2480818336\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2480818336?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-02 11:56","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2480818336","market":"us","top_or_hot":-1,"title":"Ultragenyx Pharmaceutical Inc    expected to post a loss of $1.45 a share - Earnings Preview","media":"Reuters","content":"<html><body><p>* <a href=\"https://laohu8.com/S/RARE\">Ultragenyx Pharmaceutical Inc</a>     is expected to show a rise in quarterly revenue when it reports  results on November 5 for the period ending September 30 2024</p><p>   * The Novato California-based  company is expected to report a 38.5% increase in revenue to $135.794 million from $98.05 million a year ago, according to the mean estimate from 16 analysts, based on LSEG data.</p><p>   * LSEG's mean analyst estimate for Ultragenyx Pharmaceutical Inc is for a loss of $1.45 per share. </p><p>   * The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 20 \"strong buy\" or \"buy,\" 1 \"hold\" and no \"sell\" or \"strong sell.\"  </p><p>   * The mean earnings estimate of analysts was unchanged in the last three months. </p><p>   * Wall Street's median 12-month price target for Ultragenyx Pharmaceutical Inc is $82.00, above its last closing price of $50.99. </p><p>Previous quarterly performance (using preferred earnings measure in US dollars). </p><p>QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI</p><p>ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %</p><p>              E®                               MISSED  </p><p>Jun. 30 2024  -1.66       -1.69      -1.52     Beat    10.3</p><p>Mar. 31 2024  -1.76       -1.73      -2.03     Missed  -17.2</p><p>Dec. 31 2023  -1.66       -1.62      -1.52     Beat    6.1</p><p>Sep. 30 2023  -2.28       -2.08      -2.23     Missed  -7.3</p><p>Jun.        -2.08       -2.07      -2.25     Missed  -8.5</p><p>30 2023                                                </p><p>Mar. 31 2023  -2.04       -1.98      -2.33     Missed  -17.9</p><p>Dec. 31 2022  -2.19       -2.14      -2.16     Missed  -0.8</p><p>Sep. 30 2022  -2.35       -1.81      -3.50     Missed  -93</p><p>This summary was machine generated November 2 at 03:56 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ultragenyx Pharmaceutical Inc    expected to post a loss of $1.45 a share - Earnings Preview</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUltragenyx Pharmaceutical Inc    expected to post a loss of $1.45 a share - Earnings Preview\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2024-11-02 11:56</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>* <a href=\"https://laohu8.com/S/RARE\">Ultragenyx Pharmaceutical Inc</a>     is expected to show a rise in quarterly revenue when it reports  results on November 5 for the period ending September 30 2024</p><p>   * The Novato California-based  company is expected to report a 38.5% increase in revenue to $135.794 million from $98.05 million a year ago, according to the mean estimate from 16 analysts, based on LSEG data.</p><p>   * LSEG's mean analyst estimate for Ultragenyx Pharmaceutical Inc is for a loss of $1.45 per share. </p><p>   * The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 20 \"strong buy\" or \"buy,\" 1 \"hold\" and no \"sell\" or \"strong sell.\"  </p><p>   * The mean earnings estimate of analysts was unchanged in the last three months. </p><p>   * Wall Street's median 12-month price target for Ultragenyx Pharmaceutical Inc is $82.00, above its last closing price of $50.99. </p><p>Previous quarterly performance (using preferred earnings measure in US dollars). </p><p>QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI</p><p>ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %</p><p>              E®                               MISSED  </p><p>Jun. 30 2024  -1.66       -1.69      -1.52     Beat    10.3</p><p>Mar. 31 2024  -1.76       -1.73      -2.03     Missed  -17.2</p><p>Dec. 31 2023  -1.66       -1.62      -1.52     Beat    6.1</p><p>Sep. 30 2023  -2.28       -2.08      -2.23     Missed  -7.3</p><p>Jun.        -2.08       -2.07      -2.25     Missed  -8.5</p><p>30 2023                                                </p><p>Mar. 31 2023  -2.04       -1.98      -2.33     Missed  -17.9</p><p>Dec. 31 2022  -2.19       -2.14      -2.16     Missed  -0.8</p><p>Sep. 30 2022  -2.35       -1.81      -3.50     Missed  -93</p><p>This summary was machine generated November 2 at 03:56 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"RARE","symbol_name":"Ultragenyx Pharmaceutical Inc","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2480818336","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2480818336","pubTimestamp":1730519817,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"* Ultragenyx Pharmaceutical Inc     is expected to show a rise in quarterly revenue when it reports  results on November 5 for the period ending September 30 2024   * The Novato California-based  comp","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"RARE":"Ultragenyx Pharmaceutical Inc"},"translate_title":"Ultragenyx Pharmaceutical Inc预计每股亏损1.45美元-收益预览","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RARE":1},"content_text":"* Ultragenyx Pharmaceutical Inc     is expected to show a rise in quarterly revenue when it reports  results on November 5 for the period ending September 30 2024   * The Novato California-based  company is expected to report a 38.5% increase in revenue to $135.794 million from $98.05 million a year ago, according to the mean estimate from 16 analysts, based on LSEG data.   * LSEG's mean analyst estimate for Ultragenyx Pharmaceutical Inc is for a loss of $1.45 per share.    * The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 20 \"strong buy\" or \"buy,\" 1 \"hold\" and no \"sell\" or \"strong sell.\"     * The mean earnings estimate of analysts was unchanged in the last three months.    * Wall Street's median 12-month price target for Ultragenyx Pharmaceutical Inc is $82.00, above its last closing price of $50.99. Previous quarterly performance (using preferred earnings measure in US dollars). QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRIENDING        ARTESTIMAT  ESTIMATE             MET,    SE %              E®                               MISSED  Jun. 30 2024  -1.66       -1.69      -1.52     Beat    10.3Mar. 31 2024  -1.76       -1.73      -2.03     Missed  -17.2Dec. 31 2023  -1.66       -1.62      -1.52     Beat    6.1Sep. 30 2023  -2.28       -2.08      -2.23     Missed  -7.3Jun.        -2.08       -2.07      -2.25     Missed  -8.530 2023                                                Mar. 31 2023  -2.04       -1.98      -2.33     Missed  -17.9Dec. 31 2022  -2.19       -2.14      -2.16     Missed  -0.8Sep. 30 2022  -2.35       -1.81      -3.50     Missed  -93This summary was machine generated November 2 at 03:56 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"preview","news_rank":0,"symbols":[],"gpt_button":1,"code":"91000000","status":"200"}}}